This can be examined using Positron Emission Tomography (PET) imaging, where PD patients exhibit reductions in putamen dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding, compared to healthy individuals [9,10]. The gene discussed is SLC6A3; the disease is Parkinson disease.